Repeated intravenous infusion of adipose Tissue-Derived stem cells as a promising treatment for amyotrophic lateral sclerosis

We proposes that intravenous infusion therapy using adipose tissue-derived stem cells (ADSCs) holds promise as a treatment strategy for amyotrophic lateral sclerosis (ALS), a severe neurodegenerative disease impacting motor neurons. This hypothesis is supported by ADSCs' potential for neuronal repair, secretion of cytokines and nerve growth factors, and their ability to "home" to injury sites. Early-stage human clinical trials have shown the safety of ADSCs and their positive long-term outcomes. To further substantiate our hypothesis, we investigated the caspase-4 activity in ADSCs-an enzyme implicated in the degradation of TDP43, a protein that accumulates in ALS neurons. ELISA assays confirmed the presence of caspase-4 activity in ADSCs, strengthening the rationale behind ADSC administration for ALS treatment. Exploring the therapeutic potential of ADSCs in ALS offers promise and could significantly influence treatment approaches, potentially enhancing patient outcomes and quality of life. Proof of this hypothesis is feasible through double-blind randomized controlled trials, which are the gold standard in scientific validation. We anticipate that this proposed therapeutic hypothesis will catalyze progress in clinical trials, expediting the path towards a cure for ALS.